Iron (III) hydroxide sucrose complex, 20 mg/ml 5 pcs 5 pcs
€94.66 €82.04
Pharmacotherapeutic group:
Pharmacotherapy group:
ATC:
B.03.A.C.02 Iron oxide saccharate
Pharmacodynamics:
The multinuclear centers of iron (III) hydroxide are surrounded by many noncovalently bound sucrose molecules on the outside. This results in a complex with a molecular weight of approximately 43 kDa, making it impossible to excrete it unchanged through the kidneys.
This complex is stable and does not release iron ions under physiological conditions. The structure of the multinuclear iron-containing nucleus is similar to that of ferritin, the physiological iron depot. This complex is designed to create a controlled source of utilizable iron for transferrin and ferritin, which are responsible for transport and deposition of iron in the body.
After intravenous administration, iron from this complex is taken up primarily by the liver, spleen and bone marrow and then used for the synthesis of hemoglobin, myoglobin and other iron-containing enzymes, or stored in the liver in the form of ferritin.
Pharmacokinetics:
After a single intravenous administration of Iron [III] hydroxide sucrose complex containing 100 mg of iron, maximum iron concentration, averaging 538 μmol, is reached 10 minutes after injection. The distribution volume of the central chamber corresponds almost completely to the volume of serum (about 3 liters).
The elimination half-life is about 6 h. The volume of distribution in equilibrium is approximately 8 L, indicating low iron distribution in body fluids, due to the low stability of iron sugars compared to transferrin, there is a competitive exchange of iron in favor of transferrin and as a result, about 31 mg of iron is transported in 24 h.
The renal excretion of iron for the first 4 h after injection is less than 5% of total clearance. After 24 h, serum iron levels return to the original (pre-injection) value and approximately 75% of sucrose leaves the vascular stream.
Indications
Iron [III] hydroxide sucrose complex is used for the treatment of iron deficiency in the following cases:
- when rapid iron replenishment is necessary;
- in patients who cannot tolerate oral iron preparations or do not follow the treatment regimen;
- in the presence of active inflammatory bowel disease when oral iron preparations are ineffective.
.
How to take, the dosage
Injection: Iron [III] hydroxide sucrose complex is administered only intravenously – slowly by trickle or drip and into the venous section of the dialysis system and is not intended for intramuscular administration. A full therapeutic dose of the drug should not be administered at one time.
Before administering the first therapeutic dose, a test dose should be administered. If intolerance occurs during the observation period, the drug administration should be stopped immediately. Before opening the ampoule should be inspected for possible precipitate and damage. Only the brown solution without residue may be used.
Drip administration: Iron [III] hydroxide sucrose complex is preferably administered by drip infusion in order to reduce the risk of marked decreases in arterial pressure (BP) and the risk of the solution entering the pericolumnar space. Immediately prior to infusion, the preparation Iron [III] hydroxide sucrose complex should be diluted with 0.9% sodium chloride solution at a ratio of 1:20 [e.g., I ml (20 mg of iron) in 20 ml of 0.9% sodium chloride solution]. The resulting solution is administered at the following rate: 100 mg of iron in at least 15 min; 200 mg of iron in 30 min; 300 mg of iron in 1.5 h; 400 mg of iron in 2.5 h; 500 mg of iron in 3.5 h. The maximum tolerated single dose of 7 mg of iron/kg body weight should be administered for at least 3.5 hours, regardless of the total dose of the drug.
Before the first drip administration of a therapeutic dose of Iron [III] hydroxide sucrose complex, a test dose: 20 mg of iron in adults and children with a body weight greater than 14 kg and half the daily dose (1.5 mg of iron/kg) in children with a body weight less than 14 kg should be given for 15 min. If there are no adverse events, the remainder of the solution should be administered at the recommended rate.
Stroke administration: Iron [III] hydroxide sucrose complex can also be administered as an undiluted solution intravenously slowly, at a rate of (normal) 1 ml of Iron [III] hydroxide sucrose complex (20 mg of iron) in one minute (5 ml of Iron [III] hydroxide sucrose complex (100 mg of iron) administered in at least 5 min). The maximum volume of the drug should not exceed 10 ml of the preparation of Iron [III] hydroxide sucrose complex (200 mg of iron) in one injection.
Before the first jet injection of the therapeutic dose of Iron [III] hydroxide sucrose complex, a test dose should be administered: 1 ml of Iron [III] hydroxide sucrose complex (20 mg of iron) to adults and children with a body weight greater than 14 kg, and half the daily dose (1.5 mg of iron/kg) to children with a body weight less than 14 kg for 1-2 min. If there are no adverse events during the next 15 min of observation, the remainder of the solution should be administered at the recommended rate. After injection, the patient is advised to fix the arm in an extended position for some time.
Injection into the dialysis system: Iron [III] hydroxide sucrose complex can be injected directly into the venous area of the dialysis system, strictly following the rules described for intravenous injection.
Dose calculation: The dose is calculated individually according to the total iron deficiency in the body using the formula:
Total iron deficiency (mg) = body weight (kg) x (patient’s normal Hb – Hb level) (g/l) x 0.24* + deposited iron (mg).
For patients with a body weight less than 35 kg: normal Hb = 130 g/l, amount of iron deposited = 15 mg/kg body weight.
For patients with a body weight of more than 35 kg: normal Hb = 150 g/l, amount of iron deposited = 500 mg.
*Factor 0.24 = 0.0034 x 0.07 x 1000 (Hb iron content = 0.34%; blood volume = 7% of body weight; factor 1000 = conversion of “g” to “mg”).
The total volume of Iron [III] hydroxide sucrose complex to be administered (in ml) = Total iron deficiency (mg)/20 mg/mL.
Body weight (kg) | Cumulative therapeutic dose of Iron [III] hydroxide sucrose complex for administration: | |||||||||||
Hb 60 g/l | Hb 75 g/l | Hb 90 g/l | Hb 105 g/l | |||||||||
mg Fe | ml | mg Fe | ml | mg Fe | mL | mg Fe | mg Fe ml | |||||
5 | 160 | 8 | 140 | 7 | 120 | 6 | 100 | 5 | ||||
10 | 320 | 16 | 280 | 14 | 240 | 12 | 220 | 11 | ||||
15 | | 24 | 420 | 21 | 380 | 19 | 320 | 16 | ||||
20 | 640 | 32 | 560 | 28 | 500 | 25 |
21 | |||||
25 | 800 | 40 | 700 | 35 | 620 | 31 < | 520 | 26 | ||||
30 | 960 | 48 | 840 | 42 | 740 | 37 | 640 | 32 | ||||
35 | 1260 | 63 | 1140 | 57 | 1000 | 50 | 880 | 44 | ||||
40 | 1360 | | 1220 | 61 | 1080 | 54 | 940 | 47 | ||||
45 | 1480 | 74 | 1320 | 66 | 1,140 | 57 | 980 | 49 | ||||
50 | 1580 | 79 | 1400 | 70 | 1220 | 61 | 52 | |||||
55 | 1680 | 84 | 1500 | 75 | 1300 | 65 | 1,100 | 55 | ||||
60 | 1800 | 90 | 1580 | 79 | 1360 | 1,140 | 57 | |||||
1900 | 95 | 1680 | 84 | 1440 | 72 | 1200 | 60 | |||||
70 | 2020 | 101 | 1760 | 88 | 75 | 1260 | ||||||
75 | 2120 | 106 | 1860 | 93 | 1580 | 79 | 1320 | 66 | ||||
80 | 2220 | 111 | 1940 | 1660 | 83 | 68 | ||||||
85 | 2340 | 117 | 2040 | 102 | 1720 | 86 | 1420 | 71 | ||||
90 | 2440 | 122 | 106 | 1800 | | 1480 | 74 |